Vincristine (Oncovin)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Notable side effects

Patient drug information

History of changes in FDA indication

  • 7/10/1963: Initial FDA approval

Also known as

Precise Name: vinCRIStine Sulfate (RXCUI 11203)

Alcrist Biocrist Biocrystin Cellcristin Citomid Citomid RU Crivosin Cytomid
Farmistin CS Fauldvincri Krebin Kyocristine Nevexitin Oncocristin AQ Oncovin ELI Lilly Oncovin INJ.LSG.
Oncovin Yamakawa Onkocristin P&U Vincristine Pericristine Pharmacristine Tecnocris Trav Vincristine Vero Vincristin
Vincasar Vincasar PFS Vinces Vincosid Vincran Vincrex Vincrifil Vincrin
Vincrisin Vincrisol Vincristin Vincristina Vincristina Faulding Vincristina Filaxis Vincristina Martian Vincristin Biosyn
Vincristin CS Vincristine Vincristine Abic Vincristine Comp Vincristine DBL Vincristine Lederle Vincristine Mayne Vincristine Mayne Pharma ( BEN )
Vincristine Pharmachemie Vincristinesulfaat Vincristine Sulfate Vincristine Sulfate Synthelabo Vincristine Sulp Vincristine Sulphate Vincristine Teva Vincristinsulfat
Vincristin Sulfate Vincristinum Vincrisul Vinracin Vinracine Vinstin Vintec


  1. 1.0 1.1 Vincristine (Oncovin) package insert
  2. Vincristine (Oncovin) package insert (locally hosted backup)
  3. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. link to original article contains verified protocol PubMed
  4. Vincristine (Oncovin) patient drug information (Chemocare)
  5. Vincristine (Oncovin) patient drug information (UpToDate)